Latest Oxaliplatin Stories
THOUSAND OAKS, Calif., Sept.
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world. Fortunately physicians today have an abundance of drug therapies available to improve survival length for more advanced cancer patients.
LAKE FOREST, Ill., Aug. 11 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval and launch of oxaliplatin injection in the United States.
THOUSAND OAKS, Calif., Aug.
BETHESDA, Md. and BRIDGEWATER, N.J., Aug.
THOUSAND OAKS, Calif., July 17 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved revisions to the U.S.
-- Has Tentative FDA Approval and Expects Final Approval Shortly -- LAKE FOREST, Ill., June 18 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that the U.S.
The combination of chemotherapies 5FU and oxaliplatin compared to 5FU alone after surgery for colon cancer decreases colon cancer recurrence and promotes longer survival for patients under 70 -- but not for those who are older.
- New Progression-Free Survival, Disease Control and Neurotoxicity Data To Be Presented at 2009 ASCO Annual Meeting Continue to Support Picoplatin as a Neuropathy-Sparing Alternative to Oxaliplatin for First-Line Treatment of Colorectal Cancer - - Poniard Management Team to Host Analyst and Investor Briefing to Discuss Data on Sunday, May 31st - SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.
Novel chemotherapy and biological agents for metastatic colorectal cancer, combined with surgical advances in liver resection, have resulted in a dramatic increase in survival for patients with advanced disease